$ALECOct 5, 2026, 7:00 AM ETAI processed
Alector licenses brain-penetrant GCase ERT AL050 to Genentech — $100M upfront, up to $1.17B in milestones
AI Summary
Alector granted Genentech exclusive global rights to AL050, an engineered, brain‑penetrant glucocerebrosidase (GCase) enzyme replacement therapy delivered via Alector’s Brain Carrier (ABC); Genentech will lead development, manufacturing and commercialization. Alector will receive $100M upfront, up to $1.17B in development/regulatory/commercial milestones plus tiered royalties, and says the deal extends its cash runway into 2029 to advance other brain-enabled programs (AL137, AL164, AL062).
Positives
- $100M upfront plus up to $1.17B in contingent development, regulatory and commercial milestone payments, plus tiered royalties
- Genentech assumes responsibility for development, manufacturing and commercialization, de-risking Alector’s expenditures on AL050
- Company states the deal extends cash runway into 2029 to advance other brain-enabled programs (AL137, AL164, AL062)
Negatives
- AL050 is investigational/early-stage and remains subject to development and regulatory risk
- Alector granted away global rights to AL050, limiting direct upside to milestones and royalties